Triple negative breast cancer, or TNBC, constitutes approximately 15% of all breast cancer cases. It is an aggressive type of breast cancer, which lacks receptors for estrogen (ER), progesterone (PR), and human epidermal growth factor2 (Her2). Since many of the current breast cancer treatments target these receptors, less than optimal results are often achieved for TNBC patients. It comes as no surprise, then, that we’ve noticed an increase in requests from researchers requesting triple negative breast cancer samples...
Yesterday, we announced an expanded relationship with BioServe Network member Fox Chase Cancer Center, who will offer our clients next generation sequencing (NGS) capabilities.
As you know, performing NGS on our DNA samples provides our customers with a powerful solutions including – in the case of oncology – the identification and investigation of specific genetic changes, mutations, or copy number variations present in tumor vs. normal adjacent tissue. This promises to yield a treasure trove of clinically relevant information, such as:
Follow @bioserve on Twitter for insights, news and opinions that help your research.
Bioserve just added 40 new lung cancer tissue samples to our repository; this Wednesday we'll add 30 samples. You'd know, and your research would benefit, if you joined the conversation @bioserve on Twitter, where you'll get the latest updates on new inventory and the newest sample deals and discounts, plus insight and opinion on the role of tissue samples in your research.
Check out our inventory update page for the newest samples added to our inventory.
Now through November 30th, 2011, order any RNA samples from BioServe and fetch a 25% discount.
Our Global BioRepository contains RNA isolated from fresh frozen tumors from over 1,400 donors. Each aliquot is analyzed for quality via Agilent’s BioAnalyzer.
Included in this collection are more than 500 “matched pairs” - RNA from highly-annotated tumor and normal adjacent tissue samples. Cancer types include renal, prostate, pancreatic, ovarian, lung, liver, breast and colon cancer. We also maintain a significant inventory of tissue RNA from inflammatory bowel disease and Crohn’s disease.
This offer cannot be combined with our 2011 Year-End Deal...
You didnt get the deal? Sign up for our Deal of the Month Newsletter (on the right sidebar) and we'll send it to you right away!
BioServe gave a presentation detailing the BioServe Network program at the 4th annual Biospecimen Research Network (BRN) symposium last week.
Our poster was co-authored by members from each of the Network member institutions: Fox Chase Cancer Center, the Fairbanks Institute for Healthy Communities, UMass Medical School, the Windber Research Institute, and Maine Medical Center. We generated a lot of positive feedback during the poster session on Monday night.
For me, the highlight of the BRN symposium didn't take place during the actual meeting however...